September 1, 2012Circulation Heart Failure
PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) Trial
Key result
Chronic sildenafil therapy (20 mg to 60 mg tid) is being evaluated in the RELAX trial to determine its effect on peak oxygen consumption in patients with heart failure with preserved ejection fraction.
Why the study?
Does sildenafil improve exercise capacity and clinical status in patients with HFpEF?
Population
Patients with heart failure with preserved ejection fraction (HFpEF) or 'diastolic HF'
Design
Other
Follow-up
24 weeks
Authors
Discussion
Loading...
Member takes
Implication
Sildenafil's role in HFpEF exercise capacity remains unproven; RELAX extends PDE5i evaluation via dedicated RCT with peak VO2 primary endpoint.
Study Design
Type
RCT
Multicenter
Yes
Structured PICO
Does sildenafil improve exercise capacity and clinical status in patients with HFpEF?
P
Population
Patients with heart failure with preserved ejection fraction (HFpEF) or 'diastolic HF'
I
Intervention
Sildenafil 20 mg tid for 12 weeks followed by 60 mg tid for 12 weeks
O
Outcome
Change in peak oxygen consumptionsurrogate
This paper describes the design and rationale of the RELAX trial, which investigates whether sildenafil improves exercise capacity in patients with HFpEF.
Cite This Study
Redfield et al. (2012) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF). sildenafil was evaluated on change in peak oxygen consumption. Chronic sildenafil therapy (20 mg to 60 mg tid) is being evaluated in the RELAX trial to determine its effect on peak oxygen consumption in patients with heart failure with preserved ejection fraction.